Materials and Methods
Total Page:16
File Type:pdf, Size:1020Kb
Load more
										Recommended publications
									
								- 
												
												Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep
animals Article Pharmacokinetics of Salicylic Acid Following Intravenous and Oral Administration of Sodium Salicylate in Sheep Shashwati Mathurkar 1,*, Preet Singh 2 ID , Kavitha Kongara 2 and Paul Chambers 2 1 1B, He Awa Crescent, Waikanae 5036, New Zealand 2 School of Veterinary Sciences, College of Sciences, Massey University, Palmerston North 4474, New Zealand; [email protected] (P.S.); [email protected] (K.K.); [email protected] (P.C.) * Correspondence: [email protected]; Tel.: +64-221-678-035 Received: 13 June 2018; Accepted: 16 July 2018; Published: 18 July 2018 Simple Summary: Scarcity of non-steroidal anti-inflammatory drugs (NSAID) to minimise the pain in sheep instigated the current study. The aim of this study was to know the pharmacokinetic parameters of salicylic acid in New Zealand sheep after administration of multiple intravenous and oral doses of sodium salicylate (sodium salt of salicylic acid). Results of the study suggest that the half-life of the drug was shorter and clearance was faster after intravenous administration as compared to that of the oral administration. The minimum effective concentration required to produce analgesia in humans (16.8 µL) was achieved in sheep for about 0.17 h in the current study after intravenous administration of 100 and 200 mg/kg body weight of sodium salicylate. However, oral administration of these doses failed to achieve the minimum effective concentration as mentioned above. This study is of significance as it adds valuable information on pharmacokinetics and its variation due to breed, species, age, gender and environmental conditions. - 
												
												Flunixin, Extension to Horses
The European Agency for the Evaluation of Medicinal Products Veterinary Medicines and Information Technology EMEA/MRL/744/00- FINAL June 2000 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS FLUNIXIN (Extension to horses) SUMMARY REPORT (2) 1. Flunixin is a non-steroidal anti-inflammatory drug (NSAID), and a non-narcotic analgesic with antipyretic activities. In veterinary medicine, it is used with meglumine as solubilizer as flunixin meglumine. Flunixin meglumine is used in the alleviation of inflammation and pain associated with musculo-skeletal disorders and colic in horses; the control of acute inflammation associated with infectious diseases in cattle and as an aid in the treatment of mastitis metritis agalactia syndrome (MMA) in sows. A dose of 2.2 mg/kg bw by the intravenous route once a day for up to 3 days is indicated for bovines, whilst 2.2 mg/kg bw intramuscularly (up to 2 injections, 12 hours apart) is recommended for sows affected by MMA syndrome. Flunixin meglumine is also used in veterinary medicine in combination with oxytetracycline for the treatment of bovine pneumonia at a dose of 2 mg/kg bw (once a day for 3 to 5 days by the intravenous or the intramuscular routes). The Committee for Veterinary Medicinal Products (CVMP) previously retained an ADI of 6 µg/kg bw (i.e. 360 µg/person) for flunixin, by applying a safety factor of 100 to the NOEL of 0.6 mg/kg bw/day which was established in a 90-day repeated dose gavage study in the dog. Flunixin is currently included in Annex I of Council Regulation (EEC) No 2377/90 in accordance with the following table: Pharmacologically Marker Animal MRLs Target tissue Other active substance(s) residue species provisions Flunixin Flunixin Bovine 20 µg/kg Muscle 30 µg/kg Fat 300 µg/kg Liver 100 µg/kg Kidney 5-Hydroxy Bovine 40 µg/kg Milk flunixin Flunixin Porcine 50 µg/kg Muscle 10 µg/kg Skin + fat 200 µg/kg Liver 30 µg/kg Kidney An application has now been received for the extention of the MRLs for flunixin to edible tissues of horses. - 
											
KETOFEN ® (Ketoprofen)
See other side for instructions for use in cattle. KETOFEN® (ketoprofen) Injectable Solution, 100 mg/mL For intravenous use in horses. PHARMACOLOGY KETOFEN is a non-narcotic, non-steroidal anti-inflammatory agent CAUTION with analgesic and antipyretic properties. Federal law restricts this drug to use by or on the order of a In horses, intravenous dosages of ketoprofen ranging from licensed veterinarian. 0.5 to 1.5 mg/lb resulted in dosage dependent anti-inflammatory effects in the chronic adjuvant carpitis model as depicted in the DESCRIPTION following graph. Ketoprofen is a non-steroidal anti-inflammatory agent of the propionic acid class that includes ibuprofen, naproxen and fenoprofen. Active Ingredient: Each mL contains 100 mg ketoprofen/mL of aqueous solution. Inactive Ingredients: 70 mg L-Arginine/mL; citric acid (to adjust pH); benzyl alcohol, 0.025 g (as preservative). It is packaged in a multiple dose bottle. INDICATION KETOFEN® (ketoprofen) is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders in the horse. DOSAGE AND ADMINISTRATION The recommended dosage is 1 mg/lb (1 mL/100 lbs) of body weight administered intravenously once daily. Treatment may be repeated for up to five days. Onset of activity is within two hours with peak response by 12 hours. Use contents within 4 months of first vial puncture. CONTRAINDICATIONS Additional studies using the same model in horses have There are no known contraindications to this drug when used as shown that the effects of ketoprofen are maximal by 12 hours directed. and still measurable at 24 hours after each dosage as depicted in Intra-arterial injection should be avoided. - 
												
												Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic
Sys Rev Pharm 2020; 11(5): 464 468 A multifaceted review journal in the field of pharmacy E-ISSN 0976-2779 P-ISSN 0975-8453 Comparative Study of the Efficacy of Flunixin, Ketoprofen and Phenylbutazone in Delman Horses with Mild Colic Agus Purnomo1, Arya Pradana Wicaksono2, Dodit Hendrawan2, Muhammad Thohawi Elziyad Purnama3* 1Department of Veterinary Surgery and Radiology, Faculty of Veterinary Medicine, Universitas Gadjah Mada, DI Yogyakarta, 55281, Indonesia 2Postgraduate Studies, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia 3Department of Veterinary Anatomy, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, 60115, Indonesia *Corresponding author E-mail: [email protected] Article History: Submitted: 26.02.2020 Revised: 16.04.2020 Accepted: 21.05.2020 ABSTRACT This study aimed to evaluate the efficacy of flunixin, ketoprofen and multiple range test. The results showed a significant alleviation in all phenylbutazone on serum biochemistry, plasma catecholamines and observed variables on Day 13, although the use of various NSAIDs serum cortisol in Delman horses with mild colic. During the study showed no significant difference. period, 32 horses were evaluated due to mild colic. Flunixin, Keywords: serum biochemical, catecholamine, cortisol, colic, NSAIDs ketoprofen, and phenylbutazone were administered intravenously at Correspondence: the recommended dose rates of 1.0; 2.2 and 4.4 mg/kg, respectively. Muhammad Thohawi Elziyad Purnama Administration of the NSAIDs commenced on Day 1 and continued Department of Veterinary Anatomy, Faculty of Veterinary Medicine, every 12 h for 12 days. Blood samples collected between days 2, 5, 9 Universitas Airlangga, Surabaya, 60115, Indonesia and 13 to evaluate AST, ALP, GGT, creatinine, urea, epinephrine, E-mail: [email protected] norepinephrine, and cortisol level. - 
												
												Food and Drug Administration, HHS § 201.323
Food and Drug Administration, HHS § 201.323 liver damage or gastrointestinal bleed- calcium, choline salicylate, magnesium ing). OTC drug products containing in- salicylate, or sodium salicylate] or ternal analgesic/antipyretic active in- other pain relievers/fever reducers. [Ac- gredients may cause similar adverse ef- etaminophen and (insert one nonste- fects. FDA concludes that the labeling roidal anti-inflammatory analgesic/ of OTC drug products containing inter- antipyretic ingredient—including, but nal analgesic/antipyretic active ingre- not limited to aspirin, carbaspirin cal- dients should advise consumers with a cium, choline salicylate, magnesium history of heavy alcohol use to consult salicylate, or sodium salicylate] may a physician. Accordingly, any OTC cause liver damage and stomach bleed- drug product, labeled for adult use, ing.’’ containing any internal analgesic/anti- (b) Requirements to supplement ap- pyretic active ingredients (including, proved application. Holders of approved but not limited to, acetaminophen, as- applications for OTC drug products pirin, carbaspirin calcium, choline sa- that contain internal analgesic/anti- licylate, ibuprofen, ketoprofen, magne- pyretic active ingredients that are sub- sium salicylate, naproxen sodium, and ject to the requirements of paragraph sodium salicylate) alone or in combina- (a) of this section must submit supple- tion shall bear an alcohol warning ments under § 314.70(c) of this chapter statement in its labeling as follows: to include the required warning in the (1) Acetaminophen. ‘‘Alcohol Warn- product’s labeling. Such labeling may ing’’ [heading in boldface type]: ‘‘If you be put into use without advance ap- consume 3 or more alcoholic drinks proval of FDA provided it includes the every day, ask your doctor whether exact information included in para- you should take acetaminophen or graph (a) of this section. - 
												
												(Ketorolac Tromethamine Tablets) Rx Only WARNING TORADOL
TORADOL ORAL (ketorolac tromethamine tablets) Rx only WARNING TORADOLORAL (ketorolac tromethamine), a nonsteroidal anti-inflammatory drug (NSAID), is indicated for the short-term (up to 5 days in adults), management of moderately severe acute pain that requires analgesia at the opioid level and only as continuation treatment following IV or IM dosing of ketorolac tromethamine, if necessary. The total combined duration of use of TORADOLORAL and ketorolac tromethamine should not exceed 5 days. TORADOLORAL is not indicated for use in pediatric patients and it is NOT indicated for minor or chronic painful conditions. Increasing the dose of TORADOLORAL beyond a daily maximum of 40 mg in adults will not provide better efficacy but will increase the risk of developing serious adverse events. GASTROINTESTINAL RISK Ketorolac tromethamine, including TORADOL can cause peptic ulcers, gastrointestinal bleeding and/or perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Therefore, TORADOL is CONTRAINDICATED in patients with active peptic ulcer disease, in patients with recent gastrointestinal bleeding or perforation, and in patients with a history of peptic ulcer disease or gastrointestinal bleeding. Elderly patients are at greater risk for serious gastrointestinal events (see WARNINGS). CARDIOVASCULAR RISK NSAIDs may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk (see WARNINGS and CLINICAL STUDIES). TORADOL is CONTRAINDICATED for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery (see WARNINGS). - 
												
												Efficacy of Ketoprofen Vs. Ibuprofen and Diclofenac: a Systematic Review of the Literature and Meta-Analysis P
Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis P. Sarzi-Puttini1, F. Atzeni1, L. Lanata2, M. Bagnasco2 1Rheumatology Unit, L. Sacco University Hospital, Milan, Italy; 2Medical Department, Dompé SpA, Milan, Italy. Abstract Objective The aim of this systematic review of the literature and meta-analysis of randomised controlled trials (RCTs) was to compare the efficacy of orally administered ketoprofen with that of ibuprofen and/or diclofenac. Methods The literature was systematically reviewed in accordance with the Cochrane Collaboration guidelines. The search was restricted to randomised clinical trials published in the Medline and Embase databases up to June 2011, and comparing the efficacy of oral ketoprofen (50–200 mg/day) with ibuprofen (600-1800 mg/day) or diclofenac (75–150 mg/day). Results A total of 13 RCTs involving 898 patients met the inclusion criteria: eight comparing ketoprofen with ibuprofen, and five comparing ketoprofen with diclofenac. The results of the meta-analysis showed a statistically significant difference in efficacy in favour of ketoprofen. The difference between ketoprofen and the pooled ibuprofen/diclofenac data was also statistically significant (0.459, 95% CI 0.33-0.58; p=0.00) at all point-estimates of the mean weighted size effect. Ketoprofen was significantly superior to both diclofenac (mean = 0.422; 95% CI 0.19-0.65; p=0.0007) and ibuprofen (mean = 0.475; 95% CI 0.32-0.62; p=0.0000) at all point-estimates. Heterogeneity for the analysed efficacy outcome was not statisically significant in any of the meta-analyses. Conclusion The efficacy of orally administered ketoprofen in relieving moderate-severe pain and improving functional status and general condition was significantly better than that of ibuprofen and/or diclofenac. - 
												
												Flunixin: a Vulture-Toxic Drug
Flunixin: a vulture-toxic drug Summary of evidence that flunixin is toxic to vultures; and that meloxicam, an alternative to flunixin, is not toxic to vultures as well as a safe and effective veterinary drug Version 1: November 2016 SAVE is an international consortium of conservation and research organisations whose mission is to respond to the vulture crisis in Asia by striving to halt vulture population declines and working to minimise their negative impacts on ecological and human health. For further details go to www.save-vultures.org Flunixin: a vulture-toxic drug SAVE 11.2016 Flunixin is toxic to Gyps vultures; however, meloxicam is not toxic to Gyps vultures and an effective alternative to flunixin for veterinary purposes Aim This paper, intended for decision-makers involved in drug licensing, presents evidence of the toxicity of flunixin, a non-steroidal anti-inflammatory drug (NSAID), to Gyps vultures; and the safety, to both vultures and domesticated animals, and effectiveness, in domesticated animals, of meloxicam, an alternative NSAID. Executive summary 1. The NSAID flunixin has been found in dead wild Gyps vultures. 2. Wild vultures are exposed to NSAIDs when feeding on carcasses of domesticated ungulates treated with these drugs shortly before death. 3. Published and unpublished data from wildlife forensic investigations in Spain shows visceral gout (i.e., a clinical sign of renal failure in birds) and flunixin residue, but not diclofenac residue, in carcasses of three Eurasian griffon vultures Gyps fulvus. 4. Captive vultures are also exposed to NSAIDs through veterinary care. 5. A survey of wildlife veterinarians found the use of flunixin caused visceral gout and death in 2 out of 4 cases involving a captive Gyps vulture. - 
												
												STUDIES with NON-STEROIDAL ANTI-INFLAMMATORY DRUGS By
STUDIES WITH NON-STEROIDAL ANTI-INFLAMMATORY DRUGS by Elizabeth Ann Galbraith M.Sc., C.Biol., M.I.Biol. A thesis submitted for the degree of Doctor of Philosophy in the Faculty of Veterinary Medicine of the University of Glasgow Department of Veterinary Pharmacology M ay 1994 ProQuest Number: 11007888 All rights reserved INFORMATION TO ALL USERS The quality of this reproduction is dependent upon the quality of the copy submitted. In the unlikely event that the author did not send a com plete manuscript and there are missing pages, these will be noted. Also, if material had to be removed, a note will indicate the deletion. uest ProQuest 11007888 Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author. All rights reserved. This work is protected against unauthorized copying under Title 17, United States C ode Microform Edition © ProQuest LLC. ProQuest LLC. 789 East Eisenhower Parkway P.O. Box 1346 Ann Arbor, Ml 48106- 1346 4kh! TUT GLASGOW UNIVERSITY ) LIBRARY i To Ian ii TABLE OF CONTENTS Acknowledgements v Declaration vi Summary vii List of tables xi List of figures xv Abbreviations xvii Chapter 1 - General Introduction 1 Chapter 2 - General Material and Methods 29 Chapter 3 - Studies with Flunixin 3.1 Introduction 43 3.2 Experimental Objectives 44 3.3 Materials and Methods 45 3.4 Experiments with Flunixin 48 3.5 Results of Oral Experiments with Flunixin 49 3.6 Results of Intravenous Experiments with Flunixin 53 3.7 Results of Subcutaneous Experiments with Flunixin 55 3.8 Discussion 57 3.9 Tables and Figures - 
												
												Homogeneity and Stability in Drinking Water of Oral Nonsteroidal Anti-Inflammatory Drugs Labelled for Swine in Europe
Original research Peer reviewed Homogeneity and stability in drinking water of oral nonsteroidal anti-inflammatory drugs labelled for swine in Europe Irene Mayós, PhD; Jaume Bosch, DVM; Emili Fadurdo, BS; Josep Homedes, DVM, P hD Summary at three standard depths in the tank (high, Implications: When NSAIDs in drinking- Objectives: To verify the stability and homo- medium, and low) at 5 minutes, 12 hours, water tanks are used to treat farm animals, geneity in drinking water of five nonsteroidal and 24 hours post mixing. variability in dose may occur if the water is not adequately stirred after product addi- anti-inflammatory drugs (NSAIDs) labeled Results: No time-related statistically tion. Lack of homogeneity may produce for pigs in Europe, including oral solutions of significant differences were observed in overdose or underdose, thereby increasing ketoprofen (300 mg per mL) and paracetamol active-principle concentrations. However, the risk of adverse events and violative (200 mg per mL) and soluble powders of significant differences were detected at dif- residues in the carcasses or the possibility of sodium salicylate 100%, paracetamol (200 mg ferent sampling depths for sodium salicylate lack of efficacy, respectively. This situation is per g), and acetylsalicylic acid 100%, under and paracetamol powder and solution. Some more evident when the added product is a field conditions. variability was observed for acetylsalicylic soluble powder rather than a solution. Materials and methods: A solution of each acid, but differences were not statistically product was prepared according to label significant. Concentrations obtained at Keywords: swine, ketoprofen, paracetamol, instructions in a 300-L farm tank, without all time points and sampling depths for salicylic acid, drinking water treatment ketoprofen approached calculated values, stirring. - 
												
												Non-Steroidal Anti-Inflammatory Drugs: Pharmacokinetics and Mitigation of Procedural-Pain in Cattle
animals Article Non-Steroidal Anti-Inflammatory Drugs: Pharmacokinetics and Mitigation of Procedural-Pain in Cattle Brooklyn K. Wagner 1 , Emma Nixon 1 , Ivelisse Robles 1, Ronald E. Baynes 1, Johann F. Coetzee 2 and Monique D. Pairis-Garcia 1,* 1 Department of Population Health and Pathobiology, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA; [email protected] (B.K.W.); [email protected] (E.N.); [email protected] (I.R.); [email protected] (R.E.B.) 2 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA; [email protected] * Correspondence: [email protected] Simple Summary: Castration and disbudding, common husbandry procedures used in cattle live- stock production industries, are recognized as being painful. In the United States (U.S.), these procedures are frequently performed without pain relief. Although non-steroidal anti-inflammatory drugs (NSAIDs) are used in food-animal production systems, no such pain relief drugs are federally approved in the U.S. for controlling procedural pain in cattle to date. Recent increases in consumer, retailer and producer commitment to improving the welfare of food-animals necessitate a closer look into pain control efforts for livestock. Therefore, this review comprehensively evaluated existing literature to summarize three NSAIDs (meloxicam, flunixin and aspirin) (1) pharmacokinetics and (2) administration outcome in regard to pain control during castration and disbudding procedures, in cattle. The sample size contained notable variability and a general deficiency of validated and replicated methodologies for assessing pain in cattle represent on-going challenges. Future research Citation: Wagner, B.K.; Nixon, E.; should prioritize replication of pain assessment techniques across different experimental conditions Robles, I.; Baynes, R.E.; Coetzee, J.F.; to close knowledge gaps identified by the present study and facilitate examination of the effectiveness Pairis-Garcia, M.D. - 
												
												Analgesic Comparison of Flunixin Meglumine Or Meloxicam for Soft-Tissue Surgery in Sheep: a Pilot Study
animals Article Analgesic Comparison of Flunixin Meglumine or Meloxicam for Soft-Tissue Surgery in Sheep: A Pilot Study Abbie V. Viscardi 1,* , Emily J. Reppert 2, Michael D. Kleinhenz 2 , Payton Wise 1, Zhoumeng Lin 1,3 , Shawnee Montgomery 1, Hayley Daniell 4, Andrew Curtis 1, Miriam Martin 1 and Johann F. Coetzee 1,3 1 Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA; [email protected] (P.W.); [email protected] (Z.L.); [email protected] (S.M.); [email protected] (A.C.); [email protected] (M.M.); [email protected] (J.F.C.) 2 Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA; [email protected] (E.J.R.); [email protected] (M.D.K.) 3 Institute of Computational Comparative Medicine, College of Veterinary Medicine, Kansas State University, Manhattan, KS 66506, USA 4 Animal Sciences and Industry, College of Agriculture, Kansas State University, Manhattan, KS 66506, USA; [email protected] * Correspondence: [email protected] Simple Summary: Pain management is lacking in U.S. commercial sheep production systems. This is, in part, due to the limited amount of scientific data evaluating sheep pain responses after analgesia treatment. Non-steroidal anti-inflammatory drugs (NSAIDs), such as meloxicam (MEL) and flunixin meglumine (FLU), are the most common drug class provided to livestock species to manage pain. Citation: Viscardi, A.V.; Reppert, E.J.; Kleinhenz, M.D.; Wise, P.; Lin, Z.; Pain assessment tools, such as facial grimace scales, which use changes in facial expression to Montgomery, S.; Daniell, H.; Curtis, monitor pain, are also needed to improve pain management and sheep welfare.